VolitionRx raises $7M in registered direct offering with milestone-linked warrants for up to $14.5M additional

VOLITIONRX LTD

Gross proceeds of ~$7M from sale of 12.7M shares/pre-funded warrants at $0.55 each; warrants exercisable at $0.57.
Series A warrants expire 60 days after announcement of $10M+ milestone commercial agreements; series B expire 6 months after first FDA approval.
Potential additional $14.5M if all milestone-linked warrants exercised on cash basis; no assurance of exercise.
Net proceeds earmarked for R&D, clinical studies, product commercialization, working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.